Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended‐Release Tacrolimus (LCPT) Using Grapefruit Juice
Clinical Pharmacology in Drug Development · 2026-01 · 15 (1)
DOI: 10.1002/cpdd.70016 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 19.01.2026. Verfasst von Adekunle Alabi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Hauptthemen laut MEDLINE: Tacrolimus, Citrus paradisi, Cytochrome P-450 CYP3A, Food-Drug Interactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Veloxis Pharmaceuticals.
Abstract (Originalsprache)
Grapefruit juice (GFJ) is a known inhibitor of intestinal cytochrome P450 3A (CYP3A) metabolism leading to increased exposure to CYP3A substrates such as tacrolimus. The extended‐release tacrolimus formulation Envarsus (LCPT) exhibits prolonged absorption throughout the entire GI tract. Although a clinically significant drug–drug interaction occurs with immediate‐release tacrolimus formulations, this has not been evaluated with extended‐release formulations. This study assessed the impact of GFJ on LCPT in adult kidney transplant patients. Eleven adult kidney transplant recipients on a stable dose of LCPT were enrolled in a randomized crossover study. Participants were administered either GFJ or water during each pharmacokinetic visit, with midazolam used as a positive control. A washout period of 2–4 weeks was included between visits. Tacrolimus concentrations were determined using validated LC‐MS/MS methods. Tacrolimus AUC 0–24 was 28% higher with GFJ (GMR = 1.28, 90% CI 1.12–1.44) and C max was 73% higher (GMR = 1.73, 90% CI 1.46–2.00) compared to control. GFJ exhibited a clinically meaningful interaction with LCPT. However, the magnitude appears less than those reported with immediate‐release formulations, suggesting the extended absorption profile of LCPT may affect susceptibility to drug interactions in the intestine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Department of Pharmacy, UC San Diego Health, San Diego, CA, USA.
- Department of Medicine, UC San Diego Health, San Diego, CA, USA.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, UC San Diego, La Jolla, CA, USA.
Förderung
- Veloxis Pharmaceuticals
Zitieren
APA
Alabi, A., Kerr, J. S., Shah, M., Khan, A., Ma, J. D., Suhandynata, R. T., Momper, J. D., & Tsunoda, S. M. (2026). Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended‐Release Tacrolimus (LCPT) Using Grapefruit Juice. Clinical Pharmacology in Drug Development, 15(1). https://doi.org/10.1002/cpdd.70016
Vancouver
Alabi A, Kerr JS, Shah M, Khan A, Ma JD, Suhandynata RT, et al. Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended‐Release Tacrolimus (LCPT) Using Grapefruit Juice. Clinical Pharmacology in Drug Development. 2026;15(1). doi:10.1002/cpdd.70016
BibTeX
@article{Alabi2026,
author = {Alabi, Adekunle and Kerr, Janice S and Shah, Mita and Khan, Adnan and Ma, Joseph D and Suhandynata, Raymond T and Momper, Jeremiah D and Tsunoda, Shirley M},
title = {Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended‐Release Tacrolimus (LCPT) Using Grapefruit Juice},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {1},
doi = {10.1002/cpdd.70016}
}
EUVIMED